The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Nivo and dara +/- cyclophosphamide in R/R MM
Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, The Netherlands, discusses a prospective, multicenter, phase II trial (NCT03184194). This study investigated the efficacy and safety of daratumumab combined with nivolumab, with or without low-dose cyclophosphamide, in patients with relapsed/refractory multiple myeloma (MM). Results indicate that the combination of daratumumab and nivolumab may be a new therapeutic regimen with an acceptable safety profile. However, the addition of low-dose cyclophosphamide did not improve efficacy, and increased the frequency of infections and hematologic toxicity. Therefore, the nivolumab-daratumumab regimen was selected for further evaluation. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
